Q-omics provides the consensus-scored METTL3 profile across patient tissues and cancer cell-line models. METTL3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, METTL3 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, METTL3 RNA expression shows 20,442 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, COAD, and ACC as cancer lineages where METTL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL3 survival associations across molecular data types. METTL3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL3 RNA expression–survival associations across cancer types. High METTL3 expression shows unfavorable associations in KICH, LIHC, ACC, COAD and KIRC, but favorable associations in PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for METTL3 RNA expression.
This table summarizes METTL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for METTL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL3 shows higher tumor expression in COAD, HNSC, BLCA, LIHC, STAD and CHOL. The COAD box plot shows higher METTL3 RNA expression in tumor versus normal tissue (log2 FC = +0.955, t-test p < 0.001).
This table shows molecular features associated with METTL3 in patient tissues and cancer cell lines. In patient samples, METTL3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and PANCREAS.
